IRONWOOD PHARMACEUTICALS INC (IRWD) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for IRONWOOD PHARMACEUTICALS INC?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, IRONWOOD PHARMACEUTICALS INC's filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-11.75%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does IRONWOOD PHARMACEUTICALS INC actually do?
Answer:
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. Its primary commercial product is LINZESS (linaclotide), a GC-C agonist approved in the U.S. for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults, and functional constipation (FC) in pediatric patients. The company is also advancing apraglutide, a GLP-2 analog, for short bowel syndrome (SBS) patients dependent on parenteral support, with a confirmatory Phase III trial planned for 2026. Ironwood operates through strategic partnerships, notably with AbbVie for LINZESS in the U.S. and globally outside of China and Japan, and with AstraZeneca in China and Astellas in Japan.
Question:
What are IRONWOOD PHARMACEUTICALS INC's revenue drivers?
Answer:
Revenues are primarily generated through collaborative arrangements and license agreements related to the development and commercialization of linaclotide, with the majority coming from LINZESS sales in the U.S. through its partnership with AbbVie.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required